News summary produced by Claude AI
Volunteers in the United Kingdom have begun receiving an experimental vaccine designed to protect against H5N1, a bird flu strain that has caused widespread infection in bird populations and transmitted to some mammals. The UK Health Security Agency characterizes the current threat to humans as low, with documented cases predominantly occurring through direct contact with infected animals.
The vaccine utilizes mRNA technology, the same platform employed in current coronavirus vaccines, which allows for rapid development and large-scale manufacturing if needed. The trial aims to enroll 4,000 participants across 26 sites in England and Scotland, plus additional sites in the United States, focusing on poultry industry workers and individuals over 65 years old—groups identified as facing elevated risk. One early participant, a longtime chicken keeper from Hampshire, described the vaccination process as straightforward.
Researchers emphasize that while human-to-human transmission of H5N1 does not yet occur readily, the possibility warrants preventive action. Since 2024, approximately 116 confirmed human cases have been documented worldwide, nearly all linked to close animal contact. The study will evaluate vaccine safety and its capacity to generate adequate immune protection, with potential licensing for use if circumstances warrant.
Manufacturing capacity exists through Moderna’s facility in Oxfordshire, which currently produces coronavirus vaccines and has the ability to manufacture 100 million doses annually, expandable to 250 million doses in a pandemic scenario. The mRNA approach offers advantages over traditional egg-based vaccine production, which can be compromised by virulent avian flu strains. Earlier experimental vaccines targeting H5N1 have shown safety but limited effectiveness, though a more recent strain circulating in the United States has produced milder symptoms.
Funding for the trial comes from CEPI, a coalition focused on epidemic preparedness, which provided £40 million after US federal funding for mRNA vaccine research was reduced. Moderna has committed to ensuring rapid and affordable vaccine access to low and middle-income countries if a pandemic emerges, addressing concerns about vaccine distribution inequities observed during the coronavirus pandemic.